· 5 min read · Updated
When Should a Healthtech Startup Hire a Fractional COO?
The window is narrower than most founders think, and in healthtech it arrives sooner. Four signals, and what catching it early buys you.
Short answer. A healthtech startup is ready for a fractional COO when hiring has started and exposes gaps, customers question its compliance or operational maturity, and the next raise depends on operational credibility. Before that, with five people or fewer and no product-market fit, founders should do the operational work themselves.
Timing is the question I get asked more than almost anything else, usually by a founder who suspects they need help but isn’t sure if now is too early, too late, or about right. There’s a real window, and it’s narrower than most founders think.
Too early looks like this
If you’re still finding product-market fit (pre-revenue or barely past it, with a team of five or fewer), you almost certainly don’t need a fractional COO yet. What you need at that stage is speed and iteration, not infrastructure. Building org design and operating cadence for a company that might pivot in three months is wasted effort. This is also the stage where founders should do the operational work themselves. Not because they’ll do it perfectly, but because they need to understand their own company’s mechanics before handing any of it off.
How do you know you’re in the window?
I see the same pattern across the healthtech and medtech founders I work with, usually several of these at once.
You’ve started hiring, and it’s exposing the gaps. Two founders can run on shared context and instinct. Fifteen people can’t. The moment you’re hiring managers, not just individual contributors, the absence of org design and accountability structure starts costing you.
Customer relationships are showing strain from execution, not product. If health system or enterprise customers are asking hard questions about your compliance posture, data governance, or operational maturity, and you’re improvising the answers, that’s not a product problem. It’s an operations problem with a customer-facing consequence.
Your next raise depends on operational credibility, not just traction. Investors evaluating a Series A or Series B increasingly diligence operations directly: financial reporting, compliance posture, whether the company can execute at the next stage. Traction gets you the meeting. Operational maturity is often what gets you the term sheet.
You’re the bottleneck, and you know it. If every escalated decision, every fire, every “can you just handle this” lands on your desk no matter what it’s actually about, the company depends on you in a way that doesn’t scale and won’t survive diligence.
Too late looks like this
Honestly, it’s rarely too late in an existential sense. But waiting has a cost. Founders who wait until a crisis (a lost customer, a failed audit, a raise that stalled on operational red flags) end up doing the same build under worse conditions, with less runway and more damage to repair first. The work is the same. The environment it happens in is harder.
Why this is sharper in healthtech and medtech specifically
Healthtech and medtech compress this timeline compared to other startup categories. HIPAA compliance, FDA regulatory context for medtech specifically, and multi-stakeholder buying committees at health systems all show up earlier and matter more than they would for a typical B2B SaaS company. A healthtech company can lose a deal to an operational gap that a similarly staged company in another vertical would never even be asked about. That’s part of why the window to bring in operational infrastructure tends to arrive sooner here than founders coming from other industries expect.
The honest read
If you recognize two or more of the signals above, the window is open now, not eventually. If none of them apply yet, that’s a legitimate answer too. It just means the right move is to keep building and revisit the question in six months.
What catching it in the window buys you
Founders who move while the signals are still early get to do this in calm conditions, and that changes the work. You choose an org design because it’s right, not because someone quit. Compliance posture gets built before a health system asks, so the answer is “here it is” rather than “give us three weeks.” The operating cadence gets tested while the stakes are still low enough to iterate on it.
Six months later, the company runs without you in every decision, and the raise conversation is about where you’re going instead of what you’re missing.
Alden Levy is the founder of Engine No. 9, a fractional COO practice for healthtech and medtech founders from Seed through Series B. He trained as a bioengineer at the University of Pennsylvania and holds an MBA from Wharton.